Moderna, known for its mRNA COVID-19 vaccine, is set to reveal full Phase 3 data for its experimental cancer vaccine targeting melanoma. The results, expected this weekend, could mark a breakthrough in cancer treatment using customized mRNA technology. This data is highly anticipated as it may transform how melanoma and other cancers are treated, potentially impacting Moderna's future in biotech innovation.
Moderna shares trade at USD 248.25 on Pluang as of Oct 21, 2026 22:11 WIB, up 2.55% in the last day. The stock shows strong buying interest with 60% of orders favoring buys. Investors hold the stock for an average of 59 days, reflecting moderate-term confidence in its biotech prospects.
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech startup that develops software to assist biotech firms in managing drug discovery tasks such as finances and clinical trial scheduling. The acquisition aims to integrate Orchestra's techno...
Moderna's stock surged 7% as investors anticipate the release of late-stage melanoma vaccine data at the European Society for Medical Oncology congress in Madrid on October 24. The data involves a combination of Moderna's intismeran autogene and Merc...
